Multifocal Motor Neuropathy with Conduction Block: Current Issues in Diagnosis and Treatment

 

 Buy Article Permissions and Reprints

ABSTRACT

Multifocal motor neuropathy (MMN) with conduction block is an acquired, autoimmune-mediated neuropathy that is responsive to treatment. The clinical history is one of slowly, progressive distal weakness, which more commonly involves the upper extremities, and it affects mainly young adults. Physical examination reveals weakness without sensory loss in the distribution of individual nerves. Atrophy may be present, but hyperreflexia and spasticity are not seen. Electrophysiological studies reveal motor conduction blocks at sites not prone to compression with normal sensory responses. Immunoglobulin M anti-GM1 titers may be elevated. Treatment with human immunoglobulin or cyclophosphamide has been shown to improve strength in the majority of patients with MMN in the short term. However, motor strength and function may gradually decline over years in spite of long-term therapy.

REFERENCES

• 1 Rowland L P, Sneider N A. Amyotrophic lateral sclerosis.  N Engl J Med . 2001;  344 1688-1700
  CrossrefPubMedGoogle Scholar
• 2 Haverkamp L J, Appel V, Appel S H. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction.  Brain . 1995;  118 707-719
  CrossrefPubMedGoogle Scholar
• 3 Traynor B J, Codd M B, Corr B, Forde C, Frost E, Hardiman O M. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study.  Arch Neurol . 2000;  57 1171-1176
  CrossrefPubMedGoogle Scholar
• 4 Van den Berg-Vos M R, Visser J, Franssen H. et al . Sporadic lower motor neuron disease with adult onset: classification of subtypes.  Brain . 2003;  126 1037-1047
  PubMedGoogle Scholar
• 5 Katz J S, Wolfe G I, Andersson P B. et al . Brachial amyotrophic diplegia: a slowly progressive motor neuron disease.  Neurology . 1999;  53 1071-1076
  PubMedGoogle Scholar
• 6 Pestronk A. Multifocal motor neuropathy: diagnosis and treatment.  Neurology . 1998;  51 S22-S24
  PubMedGoogle Scholar
• 7 Chaudhry V. Multifocal motor neuropathy.  Semin Neurol . 1998;  18 73-81
  PubMedGoogle Scholar
• 8 Nobile-Orazio E. Multifocal motor neuropathy.  J Neuroimmunol . 2001;  115 4-18
  CrossrefPubMedGoogle Scholar
• 9 Parry G J. AAEM case report #30: multifocal motor neuropathy.  Muscle Nerve . 1996;  19 269-276
  PubMedGoogle Scholar
• 10 Pringle C E, Belden J, Veitch J E, Brown W F. Multifocal motor neuropathy presenting as ophthalmoplegia.  Muscle Nerve . 1997;  20 347-351
  PubMedGoogle Scholar
• 11 Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy.  Neurology . 1992;  42 506-509
  CrossrefPubMedGoogle Scholar
• 12 Magistris M, Roth G. Motor neuropathy with multifocal persistent conduction blocks.  Muscle Nerve . 1992;  15 1056-1057
  PubMedGoogle Scholar
• 13 Dumitru D. Electrodiagnostic Medicine.  Philadelphia: Hanley & Belfus; 1995
  Google Scholar
• 14 Taylor B, Wright A, Harper C, Dyck P. Natural history of 46 patients with multifocal motor neuropathy with conduction block.  Muscle Nerve . 2000;  23 900-908
  CrossrefPubMedGoogle Scholar
• 15 Katz J S, Wolfe G I, Bryan W W. et al . Electrophysiologic findings in multifocal motor neuropathy.  Neurology . 1997;  48 700-707
  CrossrefPubMedGoogle Scholar
• 16 Van Asseldonk T H J, Van den Berg H L, Van den Berg-Vos M R, Wieneke G H, Wokke J H, Franssen H. Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness.  Brain . 2003;  126 186-198
  CrossrefPubMedGoogle Scholar
• 17 Grant I A, Gruener G, Suarez G A, Litchy W J, Dyck P J. Focal fiber loss and axonal regeneration is prominent in multifocal motor neuropathy with conduction block.  Can J Neurol Sci . 1996;  1 S11
  PubMedGoogle Scholar
• 18 Kaji R, Nobuyaki O, Teruyuki T. et al . Pathological findings at the site of conduction block in multifocal motor neuropathy.  Ann Neurol . 1993;  33 152-158
  CrossrefPubMedGoogle Scholar
• 19 Van Es W H, Van den Berg H L, Franssen H. et al . Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy.  Neurology . 1997;  48 1218-1224
  CrossrefPubMedGoogle Scholar
• 20 Corse A, Chaudhry V, Crawford T, Cornblath D, Kuncl R, Griffin J. Sensory nerve pathology in multifocal motor neuropathy.  Ann Neurol . 1996;  39 319-325
  CrossrefPubMedGoogle Scholar
• 21 Willison H, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies.  Brain . 2002;  125 2591-2625
  CrossrefPubMedGoogle Scholar
• 22 Brahe C, Servidei S, Zappata S, Ricci E, Tonali P, Neri G. Genetic homogeneity between childhood-onset and adult-onset autosomal recessive spinal muscular atrophy.  Lancet . 1995;  346 741-742
  CrossrefPubMedGoogle Scholar
• 23 La Spada R A, Roling D B, Harding A E. et al . Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy.  Nat Genet . 1992;  2 301-304
  PubMedGoogle Scholar
• 24 Mouton P, Tardieu S, Gouider R. et al . Spectrum of clinical and electrophysiologic features in HNPP patients with the 17p11.2 deletion.  Neurology . 1999;  52 1440-1446
  CrossrefPubMedGoogle Scholar
• 25 Simmons Z, Mahadeen Z I, Kothary M J. Localized hypertrophic neuropathy: magnetic resonance imaging findings and long-term follow up.  Muscle Nerve . 1999;  22 28-36
  CrossrefPubMedGoogle Scholar
• 26 Saperstein D S, Amato A A, Wolfe G I. et al . Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome.  Muscle Nerve . 1999;  22 560-566
  CrossrefPubMedGoogle Scholar
• 27 Lewis R, Sumner A, Brown M, Asbury A. Multifocal demyelinating neuropathy with persistent conduction block.  Neurology . 1982;  32 958-964
  CrossrefPubMedGoogle Scholar
• 28 Carpo M, Cappellari A, Mora G. et al . Deterioration of multifocal motor neuropathy after plasma exchange.  Neurology . 1998;  50 1480-1482
  CrossrefPubMedGoogle Scholar
• 29 Pestronk A, Cornblath D R, Ilyas A A. et al . A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.  Ann Neurol . 1988;  24 73-78
  CrossrefPubMedGoogle Scholar
• 30 Van den Berg H L, Lokhorst H, Wokke J HJ. Pulsed high dose dexamethasone is not effective in patients with multifocal motor neuropathy.  Neurology . 1997;  48 1135
  PubMedGoogle Scholar
• 31 Donaghy M, Mills K R, Boniface S J. et al . Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin.  J Neurol Neurosurg Psychiatry . 1994;  57 778-783
  PubMedGoogle Scholar
• 32 Kuntzer T, Steck A J, Adams D, Regli F. Chlorambucil fails to improve patients with multifocal motor neuropathies and antibodies to gangliosides.  J Neurol Neurosurg Psychiatry . 1992;  55 857-858
  PubMedGoogle Scholar
• 33 Leger J M, Younes-Chennoufi A, Chassande B. et al . Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy.  J Neurol Neurosurg Psychiatry . 1994;  57 S46-S49
  PubMedGoogle Scholar
• 34 Dalakas M, Stein D, Otero C, Sekul E, Cupler E, McCrosky S. Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy.  Arch Neurol . 1994;  51 861-864
  PubMedGoogle Scholar
• 35 Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy.  Neurology . 1993;  43 537-544
  PubMedGoogle Scholar
• 36 Chaudhry V, Corse A, Cornblath D. et al . Multifocal motor neuropathy: responses to human immune globulin.  Ann Neurol . 1993;  33 237-242
  CrossrefPubMedGoogle Scholar
• 37 Federico P, Zochodne D W, Hahn A, Brown W F, Feasby T E. Multifocal motor neuropathy improved by IVIg: randomized, double blind, placebo controlled study.  Neurology . 2000;  55 1256-1262
  CrossrefPubMedGoogle Scholar
• 38 Van den Berg H L, Kerkhoff H, Oey P L. et al . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study.  J Neurol Neurosurg Psychiatry . 1995;  59 248-252
  CrossrefPubMedGoogle Scholar
• 39 Azulay J-P, Blin O, Pouget J. et al . Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM antibodies: a double-blind, placebo controlled study.  Neurology . 1994;  44 429-432
  PubMedGoogle Scholar
• 40 Brannagan T. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune mediated neuropathies.  Neurology . 2002;  59 S33-S40
  PubMedGoogle Scholar
• 41 Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy.  J Neurol Neurosurg Psychiatry . 1997;  63 765-769
  CrossrefPubMedGoogle Scholar
• 42 Stangel M, Hartung H P, Marx P, Gold R. Intravenous immunoglobulin treatment of neurological autoimmune diseases.  J Neurol Sci . 1998;  153 203-214
  CrossrefPubMedGoogle Scholar
• 43 Van den Berg-Vos M R, Franssen H, Wokke J H, Van Es W, Van den berg H L. Multifocal motor neuropathy: diagnostic criteria that predict the response to treatment.  Ann Neurol . 2000;  48 919-926
  CrossrefPubMedGoogle Scholar
• 44 Katz J S, Barohn R J, Kojan S. et al . Axonal multifocal motor neuropathy without conduction block or other features of demyelination.  Neurology . 2002;  58 615-620
  PubMedGoogle Scholar
• 45 Ellis C M, Leary S, Payan J. et al . Use of human intravenous immunoglobulin in lower motor neuron syndromes.  J Neurol Neurosurg Psychiatry . 1999;  67 15-19
  PubMedGoogle Scholar
• 46 Pakiam A, Parry G. Multifocal motor neuropathy without overt conduction block.  Muscle Nerve . 1998;  21 243-245
  PubMedGoogle Scholar
• 47 Pestronk A, Lopate G, Kornberg A J. et al . Distal lower motor neuron syndrome with high-titer serum IgM anti-GM1 antibodies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide.  Neurology . 1994;  44 2027-2031
  PubMedGoogle Scholar
• 48 Dalakas M C. Intravenous immune globulin therapy for neurological diseases.  Ann Intern Med . 1997;  126 721-730
  CrossrefPubMedGoogle Scholar
• 49 National Institute of Health Consensus Conference. Intravenous immunoglobulin prevention and treatment of disease.  JAMA . 1990;  264 3189-3193
  CrossrefPubMedGoogle Scholar
• 50 Brannagan T, Nagle K, Lange D, Rowland L. Complications of intravenous immune globulin treatment in neurologic disease.  Neurology . 1996;  47 674-677
  CrossrefPubMedGoogle Scholar
• 51 Bertorini T E, Nance A M, Horner L H, Greene W, Gelfand M S, Jaster J H. Complications of intravenous gammaglobulin in neuromuscular and other disease.  Muscle Nerve . 1996;  19 388-391
  PubMedGoogle Scholar
• 52 Dalakas M C. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies.  Neurology . 2002;  59 S13-S21
  CrossrefPubMedGoogle Scholar
• 53 Caress J, Cartwright M, Donofrio P, Peacock J. The clinical features of 16 cases of stroke associated with administration of IVIg.  Neurology . 2003;  60 1822-1824
  CrossrefPubMedGoogle Scholar
• 54 Go R S, Call T G. Deep vein thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications.  Mayo Clin Proc . 2000;  75 83-85
  PubMedGoogle Scholar
• 55 Elkayam O, Paran D, Milo R. et al . Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases.  Ann Rheum Dis . 2000;  59 77-80
  CrossrefPubMedGoogle Scholar
• 56 Stangel M, Hartung H P, Marx P, Gold R. Side effects of high dose intravenous immunoglobulins.  Clin Neuropharmacol . 1997;  20 358-393
  PubMedGoogle Scholar
• 57 Koski C. Therapy of CIDP and related immune-mediated neuropathies.  Neurology . 2002;  59 S22-S27
  PubMedGoogle Scholar
• 58 Feldman E L, Bromberg M B, Albers J W, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy.  Ann Neurol . 1991;  30 397-401
  CrossrefPubMedGoogle Scholar
• 59 Van den Berg-Vos M R, Van den Berg H L, Franssen H, Van Doorn A P, Merkies I SJ, Wokke J HJ. Treatment of multifocal motor neuropathy with interferon-beta1A.  Neurology . 2000;  54 1518-1521
  PubMedGoogle Scholar
• 60 Martina I SJ, van Doorn A P, Schmitz P IM, Meulstee J, van der Meche G A F. Chronic motor neuropathies: response to interferon-β1A after failure of conventional therapies.  J Neurol Neurosurg Psychiatry . 1999;  66 197-201
  PubMedGoogle Scholar
• 61 Levine T, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab.  Neurology . 1999;  52 1701-1704
  PubMedGoogle Scholar
• 62 Pestronk A, Florence J, Miller T, Choksi R. Al-Lozi MT, Levine TD.  Treatment with IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry . 2003;  74 485-489
  PubMedGoogle Scholar
• 63 Van den Berg-Vos M R, Franssen H, Wokke J H, Van den Berg H L. Multifocal motor neuropathy: long term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment.  Brain . 2002;  125 875-1886
  PubMedGoogle Scholar
• 64 Van den Berg H L, Franssen H, Wokke J H. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy.  Brain . 1998;  121 421-428
  CrossrefPubMedGoogle Scholar
• 65 Elliot J, Pestronk A. Progression of multifocal motor neuropathy during apparently successful treatment with human immunoglobulin.  Neurology . 1994;  44 9667-9668
  PubMedGoogle Scholar
• 66 Azulay J P, Rihet P, Pouget J. et al . Long term follow up of multifocal motor neuropathy under treatment.  J Neurol Neurosurg Psychiatry . 1997;  62 391-394
  PubMedGoogle Scholar